Repurposing antifungals: population pharmacokinetics of itraconazole and hydroxy-itraconazole following administration of a nanocrystal formulation
Abstract Objectives To describe itraconazole and hydroxy-itraconazole pharmacokinetics following intravenous (IV) administration of a previously developed nanocrystal formulation (NCF) in haematopoietic cell transplant (HCT) recipients for prophylaxis of invasive fungal disease. Methods In a prospec...
Gespeichert in:
| Veröffentlicht in: | Journal of antimicrobial chemotherapy Jg. 78; H. 5; S. 1219 - 1224 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
US
Oxford University Press
03.05.2023
|
| Schlagworte: | |
| ISSN: | 0305-7453, 1460-2091, 1460-2091 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Abstract
Objectives
To describe itraconazole and hydroxy-itraconazole pharmacokinetics following intravenous (IV) administration of a previously developed nanocrystal formulation (NCF) in haematopoietic cell transplant (HCT) recipients for prophylaxis of invasive fungal disease.
Methods
In a prospective Phase II study, 10 HCT recipients received itraconazole NCF administered in 2-hour infusions of 200 mg twice daily for 2 days, followed by 200 mg once daily until Day 14. Full pharmacokinetic curves were obtained on Days 7 and 14. Additional samples were collected pre- and post-infusion until Day 6, pre-infusion on Days 10 and 12, and during washout on Days 16, 17, 18, 19 and 28. Itraconazole and hydroxy-itraconazole pharmacokinetics were analysed by non-linear mixed-effects population pharmacokinetic modelling.
Results
Four-hundred and seventy-one itraconazole and 471 paired hydroxy-itraconazole concentrations from 10 patients were included for analysis. Data were best described by a semi-mechanistic model with central and peripheral itraconazole compartments and a hydroxy-itraconazole compartment with dissolution of itraconazole drug particles from nanocrystals and first-order distribution and elimination. The final model included interindividual variability on itraconazole clearance and hydroxy-itraconazole clearance.
Conclusions
This study provides information on the pharmacokinetic properties of the itraconazole NCF useful for development of this formulation. Our results suggest that itraconazole NCF is a suitable formulation and may warrant renewal in the setting of repurposing. Our findings may be useful for the reformulation of other highly lipophilic compounds as well. |
|---|---|
| AbstractList | Abstract
Objectives
To describe itraconazole and hydroxy-itraconazole pharmacokinetics following intravenous (IV) administration of a previously developed nanocrystal formulation (NCF) in haematopoietic cell transplant (HCT) recipients for prophylaxis of invasive fungal disease.
Methods
In a prospective Phase II study, 10 HCT recipients received itraconazole NCF administered in 2-hour infusions of 200 mg twice daily for 2 days, followed by 200 mg once daily until Day 14. Full pharmacokinetic curves were obtained on Days 7 and 14. Additional samples were collected pre- and post-infusion until Day 6, pre-infusion on Days 10 and 12, and during washout on Days 16, 17, 18, 19 and 28. Itraconazole and hydroxy-itraconazole pharmacokinetics were analysed by non-linear mixed-effects population pharmacokinetic modelling.
Results
Four-hundred and seventy-one itraconazole and 471 paired hydroxy-itraconazole concentrations from 10 patients were included for analysis. Data were best described by a semi-mechanistic model with central and peripheral itraconazole compartments and a hydroxy-itraconazole compartment with dissolution of itraconazole drug particles from nanocrystals and first-order distribution and elimination. The final model included interindividual variability on itraconazole clearance and hydroxy-itraconazole clearance.
Conclusions
This study provides information on the pharmacokinetic properties of the itraconazole NCF useful for development of this formulation. Our results suggest that itraconazole NCF is a suitable formulation and may warrant renewal in the setting of repurposing. Our findings may be useful for the reformulation of other highly lipophilic compounds as well. To describe itraconazole and hydroxy-itraconazole pharmacokinetics following intravenous (IV) administration of a previously developed nanocrystal formulation (NCF) in haematopoietic cell transplant (HCT) recipients for prophylaxis of invasive fungal disease.OBJECTIVESTo describe itraconazole and hydroxy-itraconazole pharmacokinetics following intravenous (IV) administration of a previously developed nanocrystal formulation (NCF) in haematopoietic cell transplant (HCT) recipients for prophylaxis of invasive fungal disease.In a prospective Phase II study, 10 HCT recipients received itraconazole NCF administered in 2-hour infusions of 200 mg twice daily for 2 days, followed by 200 mg once daily until Day 14. Full pharmacokinetic curves were obtained on Days 7 and 14. Additional samples were collected pre- and post-infusion until Day 6, pre-infusion on Days 10 and 12, and during washout on Days 16, 17, 18, 19 and 28. Itraconazole and hydroxy-itraconazole pharmacokinetics were analysed by non-linear mixed-effects population pharmacokinetic modelling.METHODSIn a prospective Phase II study, 10 HCT recipients received itraconazole NCF administered in 2-hour infusions of 200 mg twice daily for 2 days, followed by 200 mg once daily until Day 14. Full pharmacokinetic curves were obtained on Days 7 and 14. Additional samples were collected pre- and post-infusion until Day 6, pre-infusion on Days 10 and 12, and during washout on Days 16, 17, 18, 19 and 28. Itraconazole and hydroxy-itraconazole pharmacokinetics were analysed by non-linear mixed-effects population pharmacokinetic modelling.Four-hundred and seventy-one itraconazole and 471 paired hydroxy-itraconazole concentrations from 10 patients were included for analysis. Data were best described by a semi-mechanistic model with central and peripheral itraconazole compartments and a hydroxy-itraconazole compartment with dissolution of itraconazole drug particles from nanocrystals and first-order distribution and elimination. The final model included interindividual variability on itraconazole clearance and hydroxy-itraconazole clearance.RESULTSFour-hundred and seventy-one itraconazole and 471 paired hydroxy-itraconazole concentrations from 10 patients were included for analysis. Data were best described by a semi-mechanistic model with central and peripheral itraconazole compartments and a hydroxy-itraconazole compartment with dissolution of itraconazole drug particles from nanocrystals and first-order distribution and elimination. The final model included interindividual variability on itraconazole clearance and hydroxy-itraconazole clearance.This study provides information on the pharmacokinetic properties of the itraconazole NCF useful for development of this formulation. Our results suggest that itraconazole NCF is a suitable formulation and may warrant renewal in the setting of repurposing. Our findings may be useful for the reformulation of other highly lipophilic compounds as well.CONCLUSIONSThis study provides information on the pharmacokinetic properties of the itraconazole NCF useful for development of this formulation. Our results suggest that itraconazole NCF is a suitable formulation and may warrant renewal in the setting of repurposing. Our findings may be useful for the reformulation of other highly lipophilic compounds as well. To describe itraconazole and hydroxy-itraconazole pharmacokinetics following intravenous (IV) administration of a previously developed nanocrystal formulation (NCF) in haematopoietic cell transplant (HCT) recipients for prophylaxis of invasive fungal disease. In a prospective Phase II study, 10 HCT recipients received itraconazole NCF administered in 2-hour infusions of 200 mg twice daily for 2 days, followed by 200 mg once daily until Day 14. Full pharmacokinetic curves were obtained on Days 7 and 14. Additional samples were collected pre- and post-infusion until Day 6, pre-infusion on Days 10 and 12, and during washout on Days 16, 17, 18, 19 and 28. Itraconazole and hydroxy-itraconazole pharmacokinetics were analysed by non-linear mixed-effects population pharmacokinetic modelling. Four-hundred and seventy-one itraconazole and 471 paired hydroxy-itraconazole concentrations from 10 patients were included for analysis. Data were best described by a semi-mechanistic model with central and peripheral itraconazole compartments and a hydroxy-itraconazole compartment with dissolution of itraconazole drug particles from nanocrystals and first-order distribution and elimination. The final model included interindividual variability on itraconazole clearance and hydroxy-itraconazole clearance. This study provides information on the pharmacokinetic properties of the itraconazole NCF useful for development of this formulation. Our results suggest that itraconazole NCF is a suitable formulation and may warrant renewal in the setting of repurposing. Our findings may be useful for the reformulation of other highly lipophilic compounds as well. |
| Author | Ter Heine, Rob Jansen, Anouk M E Donnelly, J P Brüggemann, Roger J M Blijlevens, Nicole |
| Author_xml | – sequence: 1 givenname: Anouk M E surname: Jansen fullname: Jansen, Anouk M E email: anouk.me.jansen@radboudumc.nl – sequence: 2 givenname: Rob surname: Ter Heine fullname: Ter Heine, Rob – sequence: 3 givenname: J P orcidid: 0000-0002-8521-335X surname: Donnelly fullname: Donnelly, J P – sequence: 4 givenname: Nicole surname: Blijlevens fullname: Blijlevens, Nicole – sequence: 5 givenname: Roger J M orcidid: 0000-0002-7618-725X surname: Brüggemann fullname: Brüggemann, Roger J M |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36935381$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkU1LxDAQhoOsuB968i49iZdq0jRN600Wv2BBED2XaZruZrdNatKi9W_4h427q2AuA3mfeWeYd4pG2miJ0CnBlwRn9GoN4qrcQIl5dIAmJE5wGOGMjNAEU8xCHjM6RlPn1hjjhCXpERrTJKOMpmSCvp5l29vWOKWXAehOVb1eQu2ug9a0fQ2dMjpoV2AbEGajtOyUcIGpAtVZ_6Ph09TSN5bBaiit-RjCf0Jl6tq8b73LRmnlvLi19A4QaNBG2MF1UHvSNvt5x-iw8ivIk32dode725f5Q7h4un-c3yxCERPahZKzoswqXMQFlSWQFAhIlsWFjAWnqUhFXDH_ikLShDNCeAQ0kQzHEQYRJXSGLna-rTVvvXRd3ignZF2DlqZ3ecTTNMWEcezRsz3aF40s89aqBuyQ_x7SA-c7wPTtn0pw_pNQ7hPK9wnRb2AMiXc |
| CitedBy_id | crossref_primary_10_1093_chromsci_bmaf035 crossref_primary_10_1093_infdis_jiaf279 crossref_primary_10_1007_s13346_024_01559_0 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. 2023 The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. |
| Copyright_xml | – notice: The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. 2023 – notice: The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. |
| DBID | TOX CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1093/jac/dkad072 |
| DatabaseName | Oxford Journals Open Access Collection Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: TOX name: Oxford Journals Open Access Collection url: https://academic.oup.com/journals/ sourceTypes: Publisher – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1460-2091 |
| EndPage | 1224 |
| ExternalDocumentID | 36935381 10.1093/jac/dkad072 |
| Genre | Research Support, Non-U.S. Gov't Clinical Trial, Phase II Journal Article |
| GroupedDBID | --- -E4 .2P .GJ .I3 .XZ .ZR 0R~ 18M 1TH 29J 2WC 3O- 4.4 482 48X 53G 5GY 5RE 5VS 5WA 5WD 6.Y 70D AABZA AACZT AAJKP AAJQQ AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAWDT AAWTL ABEJV ABEUO ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABPTD ABQLI ABQNK ABQTQ ABSAR ABSMQ ABWST ABXVV ABZBJ ACCCW ACFRR ACGFO ACGFS ACIWK ACMRT ACPQN ACPRK ACUFI ACUTJ ACUTO ACYHN ACZBC ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEHUL AEJOX AEKPW AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFNX AFFZL AFIYH AFOFC AFRAH AFSHK AFXAL AFXEN AFYAG AGINJ AGKEF AGKRT AGMDO AGQXC AGSYK AGUTN AHMBA AHXPO AI. AIAGR AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APJGH APWMN AQDSO AQKUS ASPBG ATGXG ATTQO AVNTJ AVWKF AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM BZKNY C45 CAG CDBKE COF CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS ECGQY EE~ EIHJH EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HH5 HVGLF HW0 HZ~ IOX J21 J5H JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z M49 MBLQV MHKGH ML0 N9A NGC NOMLY NOYVH NTWIH NU- NVLIB O0~ O9- OAUYM OAWHX OBS OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD R44 RD5 RHF RNI ROL ROX ROZ RUSNO RW1 RXO RZF RZO TCURE TEORI TJX TMA TOX TR2 UCJ VH1 W8F WOQ X7H Y6R YAYTL YKOAZ YXANX ZGI ZKX ZXP ~91 ~A~ ABDFA ABGNP ABVGC AHMMS CGR CUY CVF ECM EIF NPM 7X8 ABPQP ADNBA AEMQT AHGBF AJBYB AJNCP ALXQX |
| ID | FETCH-LOGICAL-c413t-e75bd9f0b4b3eda18a1ae594be4c738c8c4f5555bbe36751172a36e50420ac263 |
| IEDL.DBID | TOX |
| ISICitedReferencesCount | 3 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000952024200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0305-7453 1460-2091 |
| IngestDate | Sun Sep 28 00:17:33 EDT 2025 Wed Feb 19 02:23:12 EST 2025 Tue Nov 26 06:00:02 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c413t-e75bd9f0b4b3eda18a1ae594be4c738c8c4f5555bbe36751172a36e50420ac263 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| ORCID | 0000-0002-7618-725X 0000-0002-8521-335X |
| OpenAccessLink | https://dx.doi.org/10.1093/jac/dkad072 |
| PMID | 36935381 |
| PQID | 2788801570 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_2788801570 pubmed_primary_36935381 oup_primary_10_1093_jac_dkad072 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-05-03 |
| PublicationDateYYYYMMDD | 2023-05-03 |
| PublicationDate_xml | – month: 05 year: 2023 text: 2023-05-03 day: 03 |
| PublicationDecade | 2020 |
| PublicationPlace | US |
| PublicationPlace_xml | – name: US – name: England |
| PublicationTitle | Journal of antimicrobial chemotherapy |
| PublicationTitleAlternate | J Antimicrob Chemother |
| PublicationYear | 2023 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| SSID | ssj0006568 |
| Score | 2.4349098 |
| Snippet | Abstract
Objectives
To describe itraconazole and hydroxy-itraconazole pharmacokinetics following intravenous (IV) administration of a previously developed... To describe itraconazole and hydroxy-itraconazole pharmacokinetics following intravenous (IV) administration of a previously developed nanocrystal formulation... |
| SourceID | proquest pubmed oup |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 1219 |
| SubjectTerms | Antifungal Agents - therapeutic use Drug Repositioning Hematopoietic Stem Cell Transplantation Humans Itraconazole Nanoparticles Prospective Studies |
| Title | Repurposing antifungals: population pharmacokinetics of itraconazole and hydroxy-itraconazole following administration of a nanocrystal formulation |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36935381 https://www.proquest.com/docview/2788801570 |
| Volume | 78 |
| WOSCitedRecordID | wos000952024200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1JT4NAFH7RxhgvLnWrSx0T05MTgQEGvBmj8WLtoSa9kdmIWgNNWzX1b_iHfQPYxmqiHDhA5kH43ryFtwGcSMNQ-KUO1a4TUT9lMRWoJ6kKVKhQQXnKiGLYBG-3o14v7lQJsqNfQvgxO3sS6kz3hXa4FbVuEFl27t71pgI3LCveLOtS7gesKsObWztXwfbDkCwUyvXaf19lHVYrk5FclBhvwILJ6rB8WwXF69DqlO2nJ6ekO6umGp2SFunMGlNPNuEDrW38rrn9PUCEzRLCnY7sd04G0zFeZFAt6SNtS4bkKXkcD_FKJt7zZ4MLNXmYaJv-Qr_dSJGl8reC9reOvJaCIJnIcjWcoDH6TKyhXD1vC-6vr7qXN7QaykAV6rsxNTyQOk4d6UtmtHAj4QoTxL40vuIsUpHy0wAPiVyAzoiLwAsWmgCFgyOUF7JtqGV5ZnaBCBmnaNuHRmrto-siU8k9j1teEZFv3AYcIWLJoGy7kZThcpYgCEkFQgOOv9BMcFvYWIfITP4ySjzr2qOpw50G7JQwTwmxMGYo5929P-nvw4odL18kOLIDqI2HL-YQltTr-HE0bMIi70V4bndumwVHfgJLxOEw |
| linkProvider | Oxford University Press |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Repurposing+antifungals%3A+population+pharmacokinetics+of+itraconazole+and+hydroxy-itraconazole+following+administration+of+a+nanocrystal+formulation&rft.jtitle=Journal+of+antimicrobial+chemotherapy&rft.au=Jansen%2C+Anouk+M+E&rft.au=Ter+Heine%2C+Rob&rft.au=Donnelly%2C+J+P&rft.au=Blijlevens%2C+Nicole&rft.date=2023-05-03&rft.pub=Oxford+University+Press&rft.issn=0305-7453&rft.eissn=1460-2091&rft.volume=78&rft.issue=5&rft.spage=1219&rft.epage=1224&rft_id=info:doi/10.1093%2Fjac%2Fdkad072&rft.externalDocID=10.1093%2Fjac%2Fdkad072 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0305-7453&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0305-7453&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0305-7453&client=summon |